Ultraviolet A-I phototherapy in skin diseases;Toepassingen van ultraviolet-A-I-licht binnen de fotodermatologie

Nederlands Tijdschrift voor Geneeskunde

Volumn 143, Issue 18, 1999, Pages 931-934

  Polderman, M C A ^a   Pavel, S ^a   Vermeer, B J ^a   Wintzen, M ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PSORALEN;

ATOPIC DERMATITIS; CELL PROLIFERATION; ECZEMA; PHOTOTHERAPY; PSORIASIS; REVIEW; RISK MANAGEMENT; SCLERODERMA; SKIN DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; ULTRAVIOLET A RADIATION; URTICARIA;

DERMATITIS, ATOPIC; FEMALE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; SCLERODERMA, LOCALIZED; ULTRAVIOLET THERAPY; URTICARIA PIGMENTOSA;

EID: 0033135897     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Hönigsmann H, Fitzpatrick TB, Pathak MA, Wolff K. Oral photochemotherapy with psoralens and UVA (PUVA): principles and practice. In: Fitzpatrick TB, Eisen AZ, Wolff K, Freedherg IM, Austen KF, editors. Dermatology in general medicine. Vol I. 4th ed. New York: McGraw-Hill; 1993, p. 1728.
2. Stern RS, Lange R. Non-melanoma skin cancer occurring in patients treated with PUVA five to ten years after first treatment. J Invest Dermatol 1988;91:120-4.
3. El-Ghorr AA, Norval M. Biological effects of narrow-band (311 nm TLOI) UVB irradiation: a review. J Photochem Photobiol B 1997; 38:99-106.
4. Gruijl FR de. Nadelige effecten van zonlicht op de huid. Ned Tijdschr Geneeskd 1998;142:620-5.
5. Kelfkens G, Gruijl FR de, Leun JC van der. Ozone depletion and increase in annual carcinogenic ultraviolet dose. Photochem Photobiol 1990;52:819-23.
6. National Institutes of Health summary of the Consensus Development Conference on Sunlight, Ultraviolet Radiation, and the Skin. Bethesda, Maryland, May 8-10, 1989. Consensus Development Panel. J Am Acad Dermatol 1991;24:608-12.
7. Laat A de, Leun JC van der, Gruijl FR de. Carcinogenesis induced by UVA (365-nm) radiation: the dose-time dependence of tumor formation in hairless mice. Carcinogenesis 1997;18:1013-20.
8. Gruijl FR de, Sterenborg HJCM, Forbes PD, Davies RE, Cole C, Kelfkens G, et al. Wavelength dependence of skin cancer induction by ultraviolet irradiation of albino hairless mice. Cancer Res 1993; 53:53-60.
9. Muchenberger S, Schöpf E, Simon JC. Phototherapy with UV-A-I for generalized granuloma annulare [letter]. Arch Dermatol 1997; 133:1605.
10. Krutmann J. Ultraviolet AI radiation-induced immunomodulation: high-dose UVAI therapy of atopic dermatitis. In: Krutmann J, Elmets GA, editors. Photoimmunology. Oxford: Blackwell Science; 1995.
11. Grewe M, Gyufko K, Schöpf E, Krutmann J. Lesional expression of interferon-gamma in atopic eczema. Lancet 1994;343:25-6.
12. Grewe M, Gyufko K, Krutmann J. Interleukin-10 production by cultured human keratinocytes: regulation by ultraviolet B and ultraviolet AI radiation. J Invest Dermatol 1995;104:3-6.
13. Baadsgaard O, Cooper KD, Lisby S, Wulf HC, Wantzin GL. Dose response and time course for induction of T6-DR+ human epidermal antigen-presenting cells by in vivo ultraviolet A, B. and C irradiation. J Am Acad Dermatol 1987;17(5 Pt 1):792-800.
14. Krutmann J, Czech W, Diepgen T, Niedner R, Kapp A, Schöpf E. High-dose UVAI therapy in the treatment of patients with atopic dermatitis. J Am Acad Dermatol 1992;26(2 Pt 1):225-30.
15. Kowalzick L, Kleinheinz A, Weichenthal M, Neuber K, Köhler I, Grosch J, et al. Low dose versus medium dose UV-AI treatment in severe atopic eczema. Acta Derm Venereol (Stockh) 1995;75:43-5.
16. Von Bohlen F, Kallusky J, Woll R. Die UVA-I-Kaltlichtbehandlung der atopischen Dermatitis. Allergologic 1994;8:382-4.
17. Schempp CM, Effinger T, Czech W, Krutmann J, Simon JC, Schöpf E. Charakterisierung von Non-Respondern bei der hochdosierten UVAI-Therapie der akut exazerbierten atopischen Dermatitis. Hautarzt 1997;48:94-9.
18. Kerscher M, Volkenandt M, Meurer M, Lehmann P, Plewig G, Röcken M. Treatment of localised scleroderma with PUVA bath photochemotherapy [letter]. Lancet 1994;343:1233.
19. Gruss C, Reed JA, Altmeyer P, McNutt NS, Kerscher M. Induction of interstitial collagenase (MMP-I) by UVA-I phototherapy in morphea fibroblasts [letter]. Lancet 1997;350:1295-6.
20. Kerscher M, Volkenandt M, Gruss C, Reuther T, Von Kobyletzki G, Freitag M, et al. Low-dose UVA phototherapy for treatment of localized scleroderma. J Am Acad Dermatol 1998;38:21-6.
21. Kolde G, Frosch PJ, Czarnetzki BM. Response of cutaneous mast cells to PUVA in patients with urticaria pigmentosa. J Invest Dermatol 1984;83:175-8.
22. Stege H, Schöpf E, Ruzicka T, Krutmann J. High-dose UVAI for urticaria pigmentosa [letter]. Lancet 1996;347:64.
23. McGrath Jr H, Bak E, Michalski JP. Ultraviolet-A light prolongs survival and improves immune function in (New Zealand black x New Zealand white) FI hybrid mice. Arthritis Rheum 1987;30:557-61.
24. McGrath jr H, Martinez-Osuna P, Lee FA. Ultraviolet-AI (340-400 nm) irradiation therapy in systemic lupus crythematosus. Lupus 1996;5:269-74.
25. McGrath jr H. Prospects for UV-AI therapy as a treatment modality in cutaneous and systemic LE. Lupus 1997;6:209-17.